Aditxt Inc. (ADTX) - Net Assets

Latest as of March 2026: $-35.17 Million USD

Based on the latest financial reports, Aditxt Inc. (ADTX) has net assets worth $-35.17 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.91 Million) and total liabilities ($49.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aditxt Inc. tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $-35.17 Million
% of Total Assets -252.93%
Annual Growth Rate N/A
5-Year Change -61.17%
10-Year Change N/A
Growth Volatility 100.35

Aditxt Inc. - Net Assets Trend (2017–2025)

This chart illustrates how Aditxt Inc. 's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Aditxt Inc. to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Aditxt Inc. (2017–2025)

The table below shows the annual net assets of Aditxt Inc. from 2017 to 2025. For live valuation and market cap data, see Aditxt Inc. market capitalisation.

Year Net Assets Change
2025-12-31 $3.95 Million -52.29%
2024-12-31 $8.29 Million -48.36%
2023-12-31 $16.05 Million +208.22%
2022-12-31 $5.21 Million -48.86%
2021-12-31 $10.18 Million -7.54%
2020-12-31 $11.01 Million +486.07%
2019-12-31 $-2.85 Million -85.60%
2018-12-31 $-1.54 Million -2465.50%
2017-12-31 $-59.90K --

Equity Component Analysis

This analysis shows how different components contribute to Aditxt Inc. 's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 20959578400.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $412.00 0.01%
Other Comprehensive Income $1.25 Million 22.36%
Other Components $214.16 Million 3817.74%
Total Equity $5.61 Million 100.00%

Aditxt Inc. Competitors by Market Cap

The table below lists competitors of Aditxt Inc. ranked by their market capitalization.

Company Market Cap
Ming Le Sports AG
F:ML2
$3.60K
American Hotel Income Properties LP
TO:HOT-U
$3.62K
NURAN WIRELESS INC.
F:1RNA
$3.81K
Soosung Innovation Co. Ltd.
KQ:084180
$3.83K
Tipco Asphalt Public Company Limited
F:TPY1
$3.56K
Smart for Life, Inc. Common Stock
NASDAQ:SMFL
$3.54K
Holdco Nuvo Group D.G Ltd. Ordinary Shares
NYSE MKT:NUVO
$3.33K
Thai Union Group Public Company Limited
F:THYG
$3.29K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Aditxt Inc. 's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 8,286,396 to 5,609,704, a change of -2,676,692 (-32.3%).
  • Net loss of 41,714,201 reduced equity.
  • Share repurchases of 9,206,442 reduced equity.
  • New share issuances of 44,128,225 increased equity.
  • Other comprehensive income increased equity by 1,254,170.
  • Other factors increased equity by 2,861,556.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-41.71 Million -743.61%
Share Repurchases $9.21 Million -164.12%
Share Issuances $44.13 Million +786.64%
Other Comprehensive Income $1.25 Million +22.36%
Other Changes $2.86 Million +51.01%
Total Change $- -32.30%

Book Value vs Market Value Analysis

This analysis compares Aditxt Inc. 's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.00x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 $0.00 $0.00 x
2018-12-31 $0.00 $0.00 x
2019-12-31 $0.00 $0.00 x
2020-12-31 $1.60 $0.00 x
2021-12-31 $1018077300.00 $0.00 x
2022-12-31 $130157675.00 $0.00 x
2023-12-31 $1499698.04 $0.00 x
2024-12-31 $71060.77 $0.00 x
2025-12-31 $150.17 $0.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Aditxt Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -743.61%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1305608.79%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 2.94x
  • Recent ROE (-743.61%) is below the historical average (-270.08%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2017 0.00% 0.00% 0.00x 0.00x $-207.01K
2018 0.00% 0.00% 0.00x 0.00x $-5.54 Million
2019 0.00% 0.00% 0.00x 0.00x $-5.54 Million
2020 -83.09% 0.00% 0.00x 1.19x $-10.25 Million
2021 -455.48% -44148.56% 0.01x 1.64x $-47.39 Million
2022 -531.09% -2961.29% 0.09x 2.06x $-28.17 Million
2023 -201.79% -5018.92% 0.01x 2.78x $-33.99 Million
2024 -415.69% -25708.85% 0.00x 3.88x $-35.27 Million
2025 -743.61% -1305608.79% 0.00x 2.94x $-42.28 Million

Industry Comparison

This section compares Aditxt Inc. 's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $155,285,360
  • Average return on equity (ROE) among peers: -101.11%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Aditxt Inc. (ADTX) $-35.17 Million 0.00% N/A $3.59K
Aardvark Therapeutics, Inc. Common Stock (AARD) $-34.80 Million 0.00% 0.00x $83.17 Million
Abcellera Biologics Inc (ABCL) $830.51 Million 14.32% 0.21x $1.61 Billion
Abeona Therapeutics Inc (ABEO) $-26.99 Million 0.00% 0.00x $321.39 Million
Acumen Pharmaceuticals Inc (ABOS) $266.97 Million -19.62% 0.16x $155.29 Million
Abpro Holdings, Inc. (ABP) $3.07 Million -479.81% 1.57x $2.00 Million
Absci Corp (ABSI) $179.13 Million -57.56% 0.19x $1.01 Billion
Arbutus Biopharma Corp (ABUS) $182.50 Million -46.25% 0.30x $831.63 Million
ABVC Biopharma Inc (ABVC) $4.59 Million -357.76% 1.38x $35.10 Million
Abivax SA American Depositary Shares (ABVX) $33.94 Million -14.97% 0.12x $7.98 Billion
ACADIA Pharmaceuticals Inc (ACAD) $113.93 Million -49.49% 0.18x $3.66 Billion

About Aditxt Inc.

NASDAQ:ADTX USA Biotechnology
Market Cap
$3.59K
Market Cap Rank
#31660 Global
#6250 in USA
Share Price
$0.00
Change (1 day)
-59.63%
52-Week Range
$0.00 - $6.60
All Time High
$2200.00
About

Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body nat… Read more